Atara Bio

Today we announced our first quarter 2024 financial results and operational progress. The latest news is available here: bit.ly/4adw4rd #celltherapy #allogeneic #CART $ATRA

Today we announced our fourth quarter and full year 2023 operational progress and financial results. The latest news is available here: bit.ly/4acaYKD #celltherapy #allogeneic #CART $ATRA

Tune in now for a cell therapy panel with CEO Pascal Touchon at Cowen Inc.’s 44th Annual Healthcare Conference. A link to the live webcast can be found in the investor section of our website: lnkd.in/gFWidVC7

We are excited to announce that Atara’s Investigational New Drug application for ATA3219, our investigational, allogeneic, anti-CD19 #CAR #Tcell therapy, has received FDA clearance in systemic lupus erythematosus (#SLE) with #lupusnephritis. Read more: bit.ly/3UTAZK0

It was a pleasure highlighting the latest developments and potential of Atara's #allogeneic #CART programs for hematological malignancies and autoimmune diseases at #JPM24. bit.ly/3vxNksE

Next week, our CEO Pascal Touchon is heading to San Francisco to share Atara's latest pipeline progress & key development milestones at the J.P. Morgan Annual Healthcare Conference on Thursday, January 11 at 9:45 a.m. PT: bit.ly/3H8hXrd #CART #JPM24

At this year's @ASH_hematology Annual Meeting, Atara will present positive preclinical data on ATA3431, our investigational next-generation #allogeneic CD20/CD19-targeted #CAR #EBV T-cell therapy for the treatment of B-cell malignancies. For more: bit.ly/3GA8b0O #ASH23

@ASH_hematology's #ASH23 is underway, and Atara is joining! If you're in San Diego, stop by our booth #1456 to learn more about our next-generation allogeneic #CART #EBV approach.

We’re heading to San Diego for #ASH23 to share positive new preclinical B-cell malignancy data for ATA3431, an investigational next-generation #allogeneic CD20/CD19-targeted CAR #EBV T-cell therapy. Be sure to stop by and check out our poster on Dec. 11.

Happening today, we are joining @myESMO to present new data from a combined analysis evaluating tab-cel® for #EBV+ CNS #PTLD during an oral session. Learn more: bit.ly/413hsYp #ESMOImmuno23

We're gearing up to join researchers and clinicians at #ESMOImmuno23. We look forward to presenting new clinical data during an oral session evaluating investigational tab-cel® for #EBV+ CNS #PTLD. Learn more: bit.ly/3GllVw7

Today we announced Atara entered an expanded global tab-cel® partnership with Pierre Fabre Laboratories. Tune in to our conference call and live webcast at 9:00 a.m. EDT to hear more and other third quarter 2023 corporate updates. bit.ly/45WNUga #EBV #MS #CART #PTLD

While autologous T-cell therapies have been life-changing for many patients, allogeneic approaches hold the promise of personalized, off-the-shelf treatments manufactured at scale, stored and ready for rapid delivery. Learn more about Atara’s approach: bit.ly/3CrLs50

Atara’s EBV T-cell platform has the potential to address a wide range of EBV-driven diseases or other serious diseases through the incorporation of engineered #CARs. Learn more about our versatile platform: bit.ly/3CrLs50

Today, our CSO & CTO, Cokey Nguyen, joins @alliancerm's #CGMesa23 to discuss how the world’s first-ever approval of an allogeneic T-cell therapy helped galvanize the #celltherapy field, paving the way to make further inroads into our fight against cancer and autoimmune disorders.

On #WorldMentalHealthDay, we emphasize our commitment to promoting mental well-being within our organization and beyond. Our Spring Health Mental Wellness Benefit empowers Atarians with the resources to focus on our mission of developing therapies to transform patients' lives.

At Atara, we are using allogeneic Epstein-Barr virus (#EBV) T cells as a platform to develop investigational therapies for cancer and autoimmune diseases. Learn more about our pipeline: bit.ly/3qq01Um

#DYK: A natural, evolutionarily honed immune response to #EBV can be repurposed to fight disease? At Atara, we harness immune cells from healthy donors as the basis of our platform to manufacture allogeneic #EBV T cells. More: bit.ly/3CrLs50

Everything we do at Atara revolves around our mission to transform patients' lives. On #RareCancerDay, we join @RareDiseases and this resilient community to honor those affected by uncommon #cancers and shed light on the challenges faced by people living with #rarecancers.

Allogeneic cell therapies can be stored in advance of patient need, ready for delivery within days. Learn more about our off-the-shelf approach: bit.ly/3fhXndG